Covid-19 roundup: AstraZeneca's candidate could elicit immune response in older patients; The EMA could approve a vaccine with less than 50% efficacy — report
With permission to resume its Covid-19 trial in the US, AstraZeneca is back in the race for emergency approval. And early results suggest the candidate could trigger an immune response in those most vulnerable to serious illness.
Immunogenicity blood tests performed on a subset of older participants showed that the candidate induced antibody and T-cell responses in older patients, two unnamed sources told the Financial Times. The results, they said, are consistent with earlier data which showed the candidate achieved “robust immune responses” in adults between 18 and 55 years old, according to the report.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.